GET DAILY SIGNALSPDS Biotechnology (PDSB) Shares Rise +102% on Positive Clinical Data
Key Takeaways
- PDS Biotechnology (PDSB) shares climbed roughly 102% over the last 30 days, from about $0.75 to approximately $1.52, driven by positive clinical data for its lead candidate PDS0301.
- The catalyst was encouraging Phase 2 results in late-line, liver-metastatic colorectal cancer, highlighted at a key opinion leader event featuring a National Cancer Institute investigator.
- Analyst support followed, with B. Riley raising its price target on PDSB to $4 from $3 while maintaining a Buy rating.
- Over the trailing three months, the stock has more than doubled after a sharp August selloff tied to the company's strategic pivot away from its PDS0101 program.
- The company plans to submit a Phase 3 protocol for PDS0301 in the fourth quarter, targeting a first-quarter 2027 trial start with a potential accelerated approval pathway.
- PDSB remains a high-volatility, clinical-stage biotech, and its outlook hinges on continued data readouts, financing, and regulatory milestones.
Company Overview and Market Position
PDS Biotechnology Corporation (PDSB) is a late-stage immunotherapy company based in Princeton, New Jersey, focused on transforming how the immune system targets and eliminates cancers. Its research is built around the proprietary Versamune platform, which is designed to activate T cells against cancer-specific antigens.
The company's lead program is PDS0301, a tumor-targeted IL-12 immunocytokine being developed primarily for metastatic colorectal cancer, alongside other solid tumor indications. Its other notable asset, PDS0101 (Versamune HPV), targets HPV16-positive cancers, including head and neck squamous cell carcinoma. As a clinical-stage developer with no approved products yet, PDSB is closely watched by investors for clinical data readouts, regulatory milestones, and its ability to fund ongoing development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
PDSB has delivered a dramatic short-term advance, rising approximately 102% over the last 30 days. The stock traded near $0.75 in early October before surging into the $1.50 range as investors reacted to positive clinical data for PDS0301.
The quarterly picture is even more pronounced but reflects meaningful volatility. Over the trailing three months, PDSB has more than doubled from roughly $0.71 in early August to approximately $1.52. That gain masks a sharp intra-quarter decline in August, when the stock fell below $0.30 following the company's decision to halt internal investment in its PDS0101 program. The subsequent recovery has been powered almost entirely by renewed confidence in PDS0301 and the broader pivot toward colorectal cancer development.
What Drove the Recent Rally
The primary driver of the recent rally was clinical data. In early October, PDS Biotechnology hosted a key opinion leader event featuring Dr. Jonathan Hernandez of the National Cancer Institute to discuss Phase 2 results for PDS0301 in advanced, liver-metastatic colorectal cancer. The data showed deepening responses, encouraging immune activity, and several complete responses, reinforcing the candidate's potential in a setting with limited effective options.
Analyst reaction amplified the move. In late October, B. Riley raised its price target on PDSB to $4 from $3 and reiterated a Buy rating, citing the data's support for a higher modeled probability of success. The firm highlighted plans to submit a Phase 3 protocol in the fourth quarter for a first-quarter 2027 start, with the possibility of an accelerated approval pathway supported by an interim overall response rate.
Corporate developments also shaped sentiment. The company announced board changes effective October 18, appointing three new directors with drug development, commercialization, and partnering experience while four prior directors resigned. These moves were framed as supporting the company's Phase 3 entry and partnership efforts for PDS0101.
Performance Over the Last Quarter
The trailing three-month trend reflects a strategic transformation. In August, PDS Biotechnology told shareholders it would halt internal investment in PDS0101, including discontinuing the Phase 3 VERSATILE-003 trial, to prioritize PDS0301 in metastatic colorectal cancer. The announcement triggered a sharp selloff that pushed shares below $0.30.
Since then, the stock has recovered as the PDS0301-focused strategy gained traction. Publication of VERSATILE-002 Phase 2 results for PDS0101 in JAMA Oncology in September provided additional clinical validation, even as the company continued to prioritize PDS0301. Financing activity, including a private placement and shareholder approval to increase authorized shares, and a subsequent strengthening of the board, underscored the company's refocused capital allocation toward its lead colorectal cancer program.
What Investors Should Watch Next
Looking ahead, the most important catalysts for PDSB center on the PDS0301 program. Investors should monitor the submission of the Phase 3 protocol in the fourth quarter and confirmation of a first-quarter 2027 trial start, as well as updated survival data expected in late first quarter and the full NCI-led publication to follow.
Other factors to watch include continued data from additional cohorts, such as HPV16-positive, prostate, and Kaposi sarcoma indications, and any strategic partnership developments for PDS0101. Financing remains a key risk given the company's clinical-stage status and cash needs, alongside continued execution of its refocused development plan and broader biotech sentiment. As always, these are informational observations rather than investment recommendations. From what I see, this is important because the next data readouts could clarify the path forward.
Using AI Tools for Market Context
In my view, automated systems can provide useful perspective on volatile names. I regularly review Tickeron’s AI Trading Bots to observe how different strategies are positioned around stocks like PDSB. These tools help highlight patterns across thousands of tickers without replacing personal analysis. The dedicated section below offers more on how I incorporate them into routine review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PDSB's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PDSB turned positive on October 29, 2026. Looking at past instances where PDSB's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on PDSB as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +19.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 90 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for PDSB moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 21 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 44 cases where PDSB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-28.546) is normal, around the industry mean (3.104). P/E Ratio (-2.203) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
Advertisement